finalizes final ppt arif
DESCRIPTION
TRANSCRIPT
![Page 1: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/1.jpg)
EFFECT OF MUCUNA PRURIENS EXTRACT AND SOME OF ITS
CONSTITUENTS ON MEMORY IN MICE
PRESENTED BY- SHAIKH ARIF H.
(PHARMACOLOGY)
UNDER GUIDANCE OF DR. KASTURE S.B.
SANJIVANI COLLEGE OF PHARMACEUTICAL EDUCATION & RESEARCH
KOPARGAON
![Page 2: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/2.jpg)
2
Content
Introduction and Review of literature Aim and Objective Plan of work Material and methods Results Discussion Conclusion Reference
![Page 3: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/3.jpg)
3
IntroductionMemory
Memory is the ability of human brain to encode, consolidate, and retrieve information.
When we receive stimulus through any of our
senses, some characteristic changes occur at the synapse that leads to formation of memory.
Depending upon the importance of
information, that information is either stored in short term or long term memory.
![Page 4: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/4.jpg)
4
Cont..
![Page 5: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/5.jpg)
5
Mechanism and Structure involved in memory:i] Cellular basis for learning and memory
Once activity goes through the cells they leave some imprints at the junction [that persist after the activity is gone]
Trace of activity is left in, nerve terminal or in post synaptic cells
so the efficiency of these synaptic junctions is changing either strengthening / weakening.
![Page 6: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/6.jpg)
6
ii] Erich R.Kandel
Erich R. Kandel studied molecular mechanisms of memory storage in Aplysia.
Aplysia are ideal to study because their nervous system has only approximately 20000 nerves seen by naked eyes.
The experiments by Kandel and his colleagues showed that the changes in the neurons of the Aplysia lasted for several weeks.
Figure: California sea hare (Aplysia californica).
![Page 7: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/7.jpg)
7
Cont..
Figure: A shock to the tail causes serotonin release from interneurons. This activates a stimulatory G protein (G), which activates adenylyl cyclase (AC), leading to production of cAMP and PKA-dependent phosphorylation of different substrates (Centre). Repeated shocks to the tail causes a persistent increase in cAMP concentration, leading to altered gene transcription and protein synthesis. This leads to growth of new synapses (Right).Where, CREB= cAMP response element-binding protein
![Page 8: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/8.jpg)
8
Review of Literature
Lieu et al., (2010): Demonstrated that dopaminergic anti-
Parkinsonian medications, such as levodopa (LD) cause drug-induced dyskinesias (DID) in the majority of patients with Parkinson's disease (PD). Mucuna pruriens, a legume extensively used in Ayurveda to treat PD, is reputed to provide anti-Parkinsonian benefits without inducing DID. They used water extract of M. pruriens seed powder.
![Page 9: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/9.jpg)
9
Cont..
Kasture et al., (2009): neuroprotective efficacy of MP and its potential rewarding effects were evaluated.
Thakaran et al., (2007): Demonstrated that Mucuna pruriens cotyledon powder (MPCP) has shown anti-parkinsonism and neuroprotective effects in animal models of Parkinson's disease.
![Page 10: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/10.jpg)
10
Cont..
Manyam et al., (2004): Mucuna pruriens possesses significantly
higher antiparkinsonism activity compared with levodopa in the 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease.
![Page 11: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/11.jpg)
11
Aim and objective:
To study effect of Mucuna pruriens
extract and some of it’s constituents
on memory in mice
![Page 12: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/12.jpg)
12
Plan of work
Literature survey Selection of drug and dose Collection of drugs and chemicals Fractionisation of extract Animal models:• Open field test (Object recognition test)- for short term
memory• Elevated plus maze model – for long term memory• Lithium induce head twitches Data collection and statistical analysis Interpretation of results
![Page 13: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/13.jpg)
13
Material and Methods
Plant Material:
Mucuna pruriens seeds Extract (Kapikachhu) Fractionated in Chloroform & Water.
Chemicals & Drug: Piracetam (Syrup), Scopolamine (ampoule), Chloroform, CMC (Carboxy methyl cellulose) etc.
Animals used: Species: Swiss Albino MiceWeight: 18-22 gmGender: Either sex
No. of groups: 24 (Each contain 5 animal).No. of animal used: 120
![Page 14: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/14.jpg)
14
Extraction (Procedure):
The standardized extract of Mucuna seeds (Himalaya Drug Co.) was
purchased.
The extract was fractionated into
Polar (Water)
Non polar (Chloroform)
Memory enhancing activity of the extracts was studied in healthy Swiss Albino mice
![Page 15: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/15.jpg)
15
Cont..
Elevated plus maze(Long term)
BY
Piracetam (100 mg/kg i.p) was used as standard drug
Scopolamine (0.4 mg/kg i. p.) antagonism was used to study the probable mode of action.
Open field model(Short term)
Lithium sulphate induced head twitches
![Page 16: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/16.jpg)
16
Phytochemical screening
Sr. No.
Phytochemical tests Aqueous fraction Chloroform fraction
1 Test for Carbohydrate Molisch's test Fehling's test Barfoed's test Benedict's test
----
++++
2 Test for Alkaloids Hager's test Mayer's test Dragendroff's test Wagner's test
----
++++
3 Test for for proteins and amino acids Biuret test Millons’s test Ninhydrin test
+++
---
4 Test for Steroids Liebermann-Burchard test Salkowski test
++
--
![Page 17: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/17.jpg)
17
Treatement schedule
Sr.no
Treatment EPMIR = (L1/L0) /L0
OFT(N-F)/(N+F)
1 Vehicle (SWFI)
2 Piracetam 100
3 Chloroform fraction of Mp extract 100
4 Chloroform fraction of Mp extract 200
5 Chloroform fraction of Mp extract 400
6 Aqueous fraction of Mp extract 100
7 Aqueous fraction of Mp extract 200
8 Aqueous fraction of Mp extract 400
9 Scopolamine 0.4
10 Chloroform fraction of Mp extract 100 + scopolamine 0.4 (on 7th day).
11 Aqueous fraction of Mp extract 100 + scopolamine 0.4 (on 7th day).
12 Piracetam 100 + Scopolamine 0.4 (on 7th day).
![Page 18: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/18.jpg)
On the day before test Mice were allowed to explore box without any
object for 2 min.
18
On the day of test, In 1st Trial (T1), two identical objects were
placed in the box.
Animal Models: (For short term)i] Open field apparatus (Object Recognition Test)
![Page 19: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/19.jpg)
The amount of time taken by each animal to complete 20 sec. exploration was measured
In 2nd Trial (T2, 90 min after T1), one old object was placed with newer one & time spent for exploring new and familiar
object was recorded.
19
Discrimination index (D) was calculated as
D = (N – F) (N + F)
Where, N- time spent for exploring new object.
F- time spent for exploring familiar object.
Cont..
![Page 20: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/20.jpg)
20
(For short term)i] Open field apparatus (Object Recognition Test)
Results
![Page 21: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/21.jpg)
21
Data was expressed as mean ± S.E.M. (n=5); ***p <0.001 as compared to control (one way ANOVA followed by Dunnett’s test); #p <0.05, ## p <0.05,###p <0.05
as compared to Scopolamine 0.4 group (Student’s t - test).
Sr. No
Treatment Discrimination Index Mean ± SEM
1 Vehicle (SWFI) 0.067±0.01299
2 Piracetam 100 0.12±0.0195***
3 Chloroform fraction of Mp extract 100 0.0825±0.0129***
4 Chloroform fraction of Mp extract 200 0.0356±0.0098
5 Chloroform fraction of Mp extract 400 0.00137±0.00045
6 Aq. Fraction of Mp extract 100 0.0962±0.0134***
7 Aq. Fraction of Mp extract 200 0.03211±0.0114
8 Aq. Fraction of Mp extract 400 -0.04376± 0.00235
9 Scopolamine 0.4 -0.09206 ±0.0325
10 Chloroform fraction of Mp extract 100 + scopolamine 0.4 -0.0331 ±0.0026 #
11 Aq. Fraction of Mp extract 100+ scopolamine 0.4 0.046 ±0.0081 ##
12 Piracetam 100 + Scopolamine 0.4 0.05707± 0.0026 ###
The discrimination Index for Open field apparatus
![Page 22: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/22.jpg)
22
Vehicle
Pira
ceta
m
Chlor
ofor
m fr
actio
n 10
0
Chlor
ofor
m fr
actio
n 20
0
Chlor
ofor
m fr
actio
n 40
0
Aqueo
us fr
actio
n 10
0
Aqueo
us fr
actio
n 20
0
Aqueo
us fr
actio
n 40
0
Scop
olam
ine
Pira
ceta
m 1
00 +
Scop
o 0.
4
Chlor
ofor
m fr
actio
n 10
0 + s
copo
0.4
Aqueo
us fr
actio
n 10
0 + s
copo
0.4
-0.15
-0.1
-0.05
0
0.05
0.1
0.15
Dis
crim
inat
ion
In
dex
***
*** ***
###
#
###
The discrimination Index for open field apparatus
![Page 23: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/23.jpg)
23
Data express in Mean ± SEM for completion of 20 sec exploration time of Novel (N) and Familiar (F) object in sec
0
50
100
150
200
250
Mean N
Mean F
Tim
e sp
ent
in e
xplo
rin
g ob
ject
s in
sec
Mea
n ±
SE
M
![Page 24: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/24.jpg)
24
Object recognition test in neonatal and adult mice
Swiss albino mice weighing 5 gm were divided in 2 groups (n =5) i.e. Group A and Group B
Animal A was subjected to object recognition test at the body weight of 5 gm (20 sec exploration)
These test is repeated again for Animal A and Animal B when these animals reached body weight of 25 gm
No drug treatment was given to these animals.
![Page 25: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/25.jpg)
25
Object recognition test in neonatal and adult mice
Results
![Page 26: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/26.jpg)
26
The discrimination Index for open field apparatus
5 gm of animal A 25 gm of animal A 25 gm of animal B0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0.04
0.045
0.05D
iscr
imin
atio
n I
nd
ex
![Page 27: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/27.jpg)
27
N F N F N F5 gm of animal A 25 gm of animal A 25 gm of animal B
0
50
100
150
200
250T
ime
of E
xplo
rati
on in
sec
Mea
n ±
SE
M
Time of Exploration in sec (Mean ± SEM)
![Page 28: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/28.jpg)
All the treatment is given for 7 successive days by
intraperitonial route(i.p)
Transfer latency was measured after 90 min of
administration on seven day and again after 24 hr i.e. on
eighth day. 28
ii] Elevated plus maze for memory
![Page 29: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/29.jpg)
29
Cont..
TL was expressed as Inflexion Ratio and calculated as
IR = (L1/L0) /L0
Where L1 is the TL on day seven and L0 is the TL on the eight day.
![Page 30: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/30.jpg)
30
ii] Elevated plus maze for memory:
Results
![Page 31: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/31.jpg)
31
Data was expressed as mean ± S.E.M. (n=5); ***p <0.001 as compare to control (one way ANOVA followed by Dunnett’s test); #p <0.001, ## p<0.001,###p <001
as compare to Scopolamine 0.4 group (Student’s t - test).
Sr. no
Treatment Inflection Ratio Mean ± SEM
1 Vehicle (SWFI) 0.06375 ± 0.012
2 Piracetam 100 0.1138 ± 0.013***
3 Chloroform fraction of Mp extract 100 0.0971 ± 0.011 ***
4 Chloroform fraction of Mp extract 200 0.0404 ± 0.0092
5 Chloroform fraction of Mp extract 400 0.01895 ± 0.0012
6 Aqueous fraction of Mp extract 100 0.08524 ± 0.0124***
7 Aqueous fraction of Mp extract 200 0.04706 ± 0.00999
8 Aqueous fraction of Mp extract 400 0.019098 ± 0.000962
9 Scopolamine 0.4 0.007 ± 0.0081
10 Chloroform fraction of Mp extract 100 + scopolamine 0.4 (on 7th day). 0.02068 ± 0.00471 #
11 Aqueous fraction of Mp extract 100 + scopolamine 0.4 (on 7th day). 0.0191 ± 0.00617 ##
12 Piracetam 100 + Scopolamine 0.4 (on 7th day). 0.03676 ± 0.00564 ###
The inflexion ratio for elevated plus maze for memory
![Page 32: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/32.jpg)
32
Vehicle
Pira
ceta
m
Chlor
ofor
m fr
actio
n 10
0
Chlor
ofor
m fr
actio
n 20
0
Chlor
ofor
m fr
actio
n 40
0
Aqueo
us fr
actio
n 10
0
Aqueo
us fr
actio
n 20
0
Aqueo
us fr
actio
n 40
0
Scop
olam
ine
Pira
ceta
m 1
00 +
Scop
o 0.
4
Chlor
ofor
m fr
actio
n 10
0 + sc
opo
0.4
Aqueo
us fr
actio
n 10
0 + s
copo
0.4
0
0.02
0.04
0.06
0.08
0.1
0.12In
flec
tion
rat
io***
***
***
# ##
###
The inflexion ratio for elevated plus maze for memory
![Page 33: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/33.jpg)
33
Data expressed as Mean ± SEM for Transfer latency on 7th and 8th day
Vehicle
Pira
ceta
m
Chlor
ofor
m fr
actio
n 10
0
Chlor
ofor
m fr
actio
n 20
0
Chlor
ofor
m fr
actio
n 40
0
Aqueo
us fr
actio
n 10
0
Aqueo
us fr
actio
n 20
0
Aqueo
us fr
actio
n 40
0
Pira
ceta
m 1
00+ sc
opo
0.4
Chlor
ofor
m fr
actio
n 10
0+ sco
po 0
.4
Aqueo
us fr
actio
n 10
0 + s
copo
0.4
Scop
olam
ine
0.4
0
20
40
60
80
100
120
7 th day
8th day
Tim
e fo
r tr
ansf
er la
ten
cy in
sec
Mea
n ±
SE
M
![Page 34: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/34.jpg)
34
iii] Lithium sulphate induced head twitches
Mice divided into group of 4 (Each group contain 5 animals)
Following treatment is given to respective group:
Group No.
Treatment No. of head twitches for 1 Hr.
1 Vehicle 2 Chloroform fraction of Mucuna pruriens extract 100mg/kg
3 Aqueous fraction of Mucuna pruriens extract 100mg/kg
4 Piracetam 100mg/kg
After 30 minutes, lithium sulphate 100mg/kg i.p administered
![Page 35: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/35.jpg)
35
Lithium sulphate administered i.p. to
mice releases serotonine from the serotonergic neuron and produces head twitches.
![Page 36: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/36.jpg)
36
iii] Lithium sulphate induced head twitches
Results
![Page 37: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/37.jpg)
37
Vehicle Chloroform fraction 100mg/kg
Aqueous fraction 100mg/kg Piracetam 100mg/kg0
10
20
30
40
50
60
70
80H
ead
Tw
ich
es in
1 H
r
***
***
Data was expressed as mean ± S.E.M. (n=5); ***p <0.001 as compared to control (one way ANOVA followed by Dunnett’s test).
***
![Page 38: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/38.jpg)
38
The memory enhancing drugs reduced lithium induces head twitches. Thus, decrease in lithium induce head twitches confirms the nootropic activity in both the fractions.
![Page 39: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/39.jpg)
39
Discussion
The pharmacological evaluation of nootropic activity of Mucuna pruriens was carried out using object recognition test, elevated plus maze model and Lithiunm sulphate induced head twiches.
The open field apparatus has been used to study object recognition, as a parameter for short term memory has been extensively used by various laboratories.
Animals differ in their ability to explore new and familiar object and therefore discrimination index and Inflection ratio was calculated. The piracetam was used as reference standard and scopolamine used as antagonist.
![Page 40: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/40.jpg)
40
Conclusion
Increase in discrimination index in the object recognition test,
increase in inflection ratio in the elevated plus maze, inhibition of scopolamine induced amnesia and decrease in lithium induce head twitches confirms the memory enhancing activity of
Mucuna pruriens.
Further studies are necessary to understand the active ingredient responsible for the activity and also to understand the mode of action.
![Page 41: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/41.jpg)
References
Kasture SB. A handbook of experiments in pre-clinical pharmacology. 1st ed, Career publications 2006; p. 97, 47.
Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Vander GR, Lees AJ. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry; 2004; 75: 1672-77.
Lieu CA, Kunselman AR, Manyam BV, Venkiteswaran K, Subramanian T. A water extract of Mucuna pruriens provides long-term amelioration of Parkinsonism with reduced risk for dyskinesias. Dept Neurol; 2010; 16 (7): 458-65.
Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res 2004;18 (9):706-12.
![Page 42: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/42.jpg)
42
Cont..
Poornachandra MN, Khanam S, Shivananda BG, Shivananda TN, Dris R. Mucuna pruriens (L.) DC - A novel drug for learning and memory retrieval. J Food Agri Envir 2005; 3 (3&4): 13-15.
Thakaran B, Dhanashekaran M, Mize Berg J, Manyam BV. Anti-Parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage. Phytother Res 2007; 21 (12): 1124-26.
Kandel ER, Spencer WA. Cellular neurophysiological approaches in the study of learning. Physiol Rev 1968; 48 (1): 65–34.
Kandel ER. The molecular biology of memory storage: A dialogue between genes and synapses. Biosci Rep 2001; 21 (5): 1030-38.
Parkinson J. An essay on the shaking plasy, J Neuropsychiatry Clin Neurosci 2002; 14 (2): 223-36.
![Page 43: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/43.jpg)
43
Cont..
Rang HP, Dale MM, Ritter JM, Moore PK, Flower RJ. Pharmacology. 6th ed.Edinburgh: Churchill Livingstone; 2007. p. 562-572.
Tripathi KD. Essentials of Medical Pharmacology. 5 thed, Jaypee Brothers, Medical Publishers limited, New Delhi, 2004; p. 84-85,93-101, 381-435.
Walker R, Whittlesea C. Clinical Pharmacy and Therapeutics. 4th ed, Churchill Livingstone Elseiver, 2007; p. 138,443,463-465.
Gelperin A. Rapid food-aversion learning by a terrestrial mollusk. Sci 1975; 189 (4202): 567–70.
Geinisman Y, Disterhoft JF, Gundersen HJG, McEchron MD, Persina IS, Power JM, Van der Zee EA, West MJ. Remodeling of Hippocampal synapse following hippocampus dependent associative learning. J Comp Neurol 2000; 417 (1): 49-59.
![Page 44: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/44.jpg)
44
Cont..
https://www.youtube.com/watch?v=30X7ORyGtGM= 07/08/12.
https://www.youtube.com/watch?v=9Wv9jrk-gXc = 09/12/12.
https://www.youtube.com/watch?v=ATR0os9w2jY, = 01/12/12.
https://www.youtube.com/watch?v=dYE6zixML1o = 09/09/12.
https://www.youtube.com/watch?v=ii4CHwVhExc= 15/11/12.
https://www.youtube.com/watch?v=-KguICny3JE= 13/08/12.
![Page 45: Finalizes final ppt arif](https://reader033.vdocument.in/reader033/viewer/2022061218/54b64d1c4a7959f4358b4579/html5/thumbnails/45.jpg)
45